iBio, Inc. (IBIO)

NYSEAMERICAN: IBIO · IEX Real-Time Price · USD
0.302
+0.005 (1.51%)
Sep 26, 2023, 9:33 AM EDT - Market open
1.51%
Market Cap 7.01M
Revenue (ttm) 61,000
Net Income (ttm) -76.03M
Shares Out 22.61M
EPS (ttm) -8.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,539
Open 0.304
Previous Close 0.298
Day's Range 0.302 - 0.309
52-Week Range 0.260 - 8.750
Beta -3.16
Analysts Hold
Price Target 4.25 (+1,307.29%)
Earnings Date Nov 13, 2023

About IBIO

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Martin B. Brenner D.V.M., Ph.D.
Employees 105
Stock Exchange NYSEAMERICAN
Ticker Symbol IBIO
Full Company Profile

Financial Performance

In 2022, iBio, Inc.'s revenue was $2.38 million, an increase of 0.51% compared to the previous year's $2.37 million. Losses were -$50.39 million, 114.7% more than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for IBIO stock is "Hold." The 12-month stock price forecast is $4.25, which is an increase of 1,307.29% from the latest price.

Price Target
$4.25
(1,307.29% upside)
Analyst Consensus: Hold
Stock Forecasts

News

iBio Announces Amendment to Credit Agreement with Woodforest

– Extends maturity date to December 31, 2023 – – Allows time to close pending sale of CDMO facility – BRYAN, Texas and SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or ...

4 days ago - GlobeNewsWire

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

– AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets –

6 weeks ago - GlobeNewsWire

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

– Board appointments solidify management team to lead iBio's AI-powered biotech strategy – BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...

3 months ago - GlobeNewsWire

iBio Forges Research Collaboration with the National Institutes of Health

– NIH to evaluate iBio's patented AI-driven epitope steering platform for Lassa fever vaccine development –

3 months ago - GlobeNewsWire

iBio to Participate in the JMP Securities Life Sciences Conference

BRYAN, Texas and SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its I...

4 months ago - GlobeNewsWire

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given to...

6 months ago - GlobeNewsWire

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

– Immuno-oncology candidate discovered using iBio's AI epitope steering platform –

6 months ago - GlobeNewsWire

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

- Company has directed antibodies against a specific region of MUC16 -

7 months ago - GlobeNewsWire

iBio Announces Closing of $3.5 Million Underwritten Public Offering

BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its pre...

10 months ago - GlobeNewsWire

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its pre...

10 months ago - GlobeNewsWire

iBio Announces Proposed Underwritten Public Offering

BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer an...

10 months ago - GlobeNewsWire

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two pos...

10 months ago - GlobeNewsWire

iBio Announces CEO Departure

BRYAN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of Directors ...

10 months ago - GlobeNewsWire

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastP...

1 year ago - GlobeNewsWire

iBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline

– Positions Company for leadership in AI-powered drug discovery –

1 year ago - GlobeNewsWire

iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update

BRYAN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming ® Manufa...

1 year ago - GlobeNewsWire

iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022

BRYAN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPhar...

1 year ago - GlobeNewsWire

iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference

BRYAN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPh...

1 year ago - GlobeNewsWire

iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update

BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufac...

1 year ago - GlobeNewsWire

iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022

BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPha...

1 year ago - GlobeNewsWire

iBio Advances Its Vaccine Program for Multi-Variant COVID-19 Disease

iBio Inc received the FDA response to its pre-investigational new drug (IND) package for IBIO-202, the Company's lead COVID-19 vaccine program.

1 year ago - Benzinga

iBio Announces Participation in the H.C. Wainwright BioConnect Conference

BRYAN, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPha...

1 year ago - GlobeNewsWire

iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022

- Shareholders Continue to Support Reverse Split and Authorized Share Proposals by a 2-to-1 Margin - - Shareholders Continue to Support Reverse Split and Authorized Share Proposals by a 2-to-1 Margin ...

1 year ago - GlobeNewsWire

iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting

BRYAN, Texas, Dec. 21, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based  FastPh...

1 year ago - GlobeNewsWire

iBio Announces Partial Adjournment of Annual Meeting to December 22

- Shareholders Presently Supporting Reverse Split and Authorized Share Proposals by a 2-to-1 Margin -

1 year ago - GlobeNewsWire